Ovarian Sertoli-Leydig and granulosa cell tumor: comparison of epidemiology and survival outcomes.

Autor: Nasioudis D; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA. dimitrios.nasioudis@uphs.upenn.edu., Mastroyannis SA; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA., F Haggerty A; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA., M Ko E; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA., Latif NA; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA.
Jazyk: angličtina
Zdroj: Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2020 Aug; Vol. 302 (2), pp. 481-486. Date of Electronic Publication: 2020 Jun 09.
DOI: 10.1007/s00404-020-05633-z
Abstrakt: Purpose: To investigate the epidemiology, clinico-pathological characteristics and outcomes of patients diagnosed with malignant ovarian Sertoli-Leydig cell tumors (SLCTs) in comparison to granulosa cell tumors (GCTs).
Methods: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were accessed and patients diagnosed with a malignant SLCT and GCT between 1988 and 2013 were selected. Demographic and clinico-pathological characteristics were compared using the Mann-Whitney and chi-square tests. Overall (OS) and cancer-specific survival (CSS) rates were estimated with the Kaplan-Meier method and compared with the log-rank test. Cox hazard models were constructed to control for confounders.
Results: A total of 175 and 1361 patients diagnosed with SLCT and GCT, respectively, were identified. Compared to patients with GCT, those with SLCT were younger (median age 32 vs. 51 years, p < 0.001) and more likely to present with larger tumors (median size 15 vs 9.5 cm, p < 0.001) confined to the ovary (77.5% vs 69.2%, p = 0.031). Patients with SLCTs had worse CSS compared to those with GCTs, p < 0.001 (5-year rate was 76.2% vs 90.7%). After controlling for the presence of extra-ovarian disease and tumor size (≤ 10 vs > 10 cm), SCLTs were associated with a worse cancer-specific mortality compared to GCTs.
Conclusions: SLCTs are extremely rare, commonly arise in premenopausal patients. They are associated with a poorer prognosis compared to GCT.
Databáze: MEDLINE
Externí odkaz: